

Ajmal Ahmad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8187947/publications.pdf>

Version: 2024-02-01

42
papers

2,515
citations

270111

25
h-index

312153

41
g-index

42
all docs

42
docs citations

42
times ranked

4246
citing authors

#	ARTICLE	IF	CITATIONS
1	Proprotein convertase furin is a driver and potential therapeutic target in proliferative diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2022, 50, 632-652.	1.3	3
2	Apocynin ameliorates NADPH oxidase 4 (NOX4) induced oxidative damage in the hypoxic human retinal Müller cells and diabetic rat retina. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 2099-2109.	1.4	18
3	CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy. , 2021, 62, 32.		17
4	Flavonoids and PI3K/Akt/mTOR Signaling Cascade: A Potential Crosstalk in Anticancer Treatment. <i>Current Medicinal Chemistry</i> , 2021, 28, 8083-8097.	1.2	19
5	Tissue Inhibitor of Metalloproteinase-3 Ameliorates Diabetes-Induced Retinal Inflammation. <i>Frontiers in Physiology</i> , 2021, 12, 807747.	1.3	8
6	Interleukin-11 Overexpression and M2 Macrophage Density are Associated with Angiogenic Activity in Proliferative Diabetic Retinopathy. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 575-588.	1.0	22
7	Galectin-1 studies in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2020, 98, e1-e12.	0.6	17
8	The Role of Neurovascular System in Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4373-4393.	1.9	49
9	Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2020, 11, 601639.	2.2	25
10	Cross-Talk between Sirtuin 1 and the Proinflammatory Mediator High-Mobility Group Box-1 in the Regulation of Blood-Retinal Barrier Breakdown in Diabetic Retinopathy. <i>Current Eye Research</i> , 2019, 44, 1133-1143.	0.7	18
11	The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2019, 10, 2752.	2.2	50
12	Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, e27-e37.	0.6	22
13	Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 1248-1260.	1.0	9
14	Association of 150 kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, e460-e467.	0.6	7
15	Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2018, 24, 394-406.	1.1	20
16	Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells. <i>Annals of Clinical and Laboratory Science</i> , 2018, 48, 137-145.	0.2	7
17	Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2017, 95, 697-704.	0.6	17
18	Association of HMGB1 with oxidative stress markers and regulators in PDR. <i>Molecular Vision</i> , 2017, 23, 853-871.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. <i>Circulation</i> , 2015, 132, 2237-2247.	1.6	38
20	Attenuation of oxidative damage-associated cognitive decline by <i>Withania somnifera</i> in rat model of streptozotocin-induced cognitive impairment. <i>Protoplasma</i> , 2013, 250, 1067-1078.	1.0	30
21	Anti-apoptotic and Anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's Rat model. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 680-687.	1.9	109
22	Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats. <i>Neurological Sciences</i> , 2013, 34, 2181-2192.	0.9	40
23	Neuroprotective efficacy of <i>Nardostachys jatamansi</i> and crocetin in conjunction with selenium in cognitive impairment. <i>Neurological Sciences</i> , 2012, 33, 1011-1020.	0.9	47
24	<i>Ocimum sanctum</i> attenuates oxidative damage and neurological deficits following focal cerebral ischemia/reperfusion injury in rats. <i>Neurological Sciences</i> , 2012, 33, 1239-1247.	0.9	36
25	Naringenin ameliorates Alzheimer's disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. <i>Neurochemistry International</i> , 2012, 61, 1081-1093.	1.9	137
26	S-allyl cysteine mitigates oxidative damage and improves neurologic deficit in a rat model of focal cerebral ischemia. <i>Nutrition Research</i> , 2012, 32, 133-143.	1.3	71
27	Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. <i>Molecular and Cellular Biochemistry</i> , 2012, 367, 215-225.	1.4	36
28	Catechin Hydrate Ameliorates Redox Imbalance and Limits Inflammatory Response in Focal Cerebral Ischemia. <i>Neurochemical Research</i> , 2012, 37, 1747-1760.	1.6	71
29	Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson's Disease. <i>Neurotoxicity Research</i> , 2012, 22, 1-15.	1.3	144
30	Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: A behavioral, biochemical and immunohistological study in Wistar rats. <i>Journal of the Neurological Sciences</i> , 2011, 309, 45-54.	0.3	81
31	Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke. <i>Experimental & Translational Stroke Medicine</i> , 2011, 3, 16.	3.2	45
32	Neuroprotective effects of curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: Behavioral, neurochemical and immunohistochemical studies. <i>Brain Research</i> , 2011, 1368, 254-263.	1.1	72
33	S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer's type. <i>Brain Research</i> , 2011, 1389, 133-142.	1.1	107
34	Hesperidin ameliorates functional and histological outcome and reduces neuroinflammation in experimental stroke. <i>Brain Research</i> , 2011, 1420, 93-105.	1.1	102
35	Quercetin Protects Against Oxidative Stress Associated Damages in a Rat Model of Transient Focal Cerebral Ischemia and Reperfusion. <i>Neurochemical Research</i> , 2011, 36, 1360-1371.	1.6	92
36	Synergistic Effect of Selenium and Melatonin on Neuroprotection in Cerebral Ischemia in Rats. <i>Biological Trace Element Research</i> , 2011, 139, 81-96.	1.9	33

#	ARTICLE	IF	CITATIONS
37	Amelioration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced behavioural dysfunction and oxidative stress by Pycnogenol in mouse model of Parkinson's disease. <i>Behavioural Pharmacology</i> , 2010, 21, 563-571.	0.8	21
38	Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. <i>Brain Research</i> , 2010, 1328, 139-151.	1.1	232
39	Sesamin attenuates behavioral, biochemical and histological alterations induced by reversible middle cerebral artery occlusion in the rats. <i>Chemico-Biological Interactions</i> , 2010, 183, 255-263.	1.7	67
40	Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. <i>Brain Research</i> , 2009, 1281, 117-127.	1.1	179
41	Rutin protects the neural damage induced by transient focal ischemia in rats. <i>Brain Research</i> , 2009, 1292, 123-135.	1.1	176
42	Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). <i>European Neuropsychopharmacology</i> , 2009, 19, 636-647.	0.3	196